Hiroyuki Abe to Neoadjuvant Therapy
This is a "connection" page, showing publications Hiroyuki Abe has written about Neoadjuvant Therapy.
Connection Strength
0.718
-
K-means clustering-based analysis of quantitative ultrafast DCE-MRI for predicting breast cancer response to neoadjuvant chemotherapy. J Appl Clin Med Phys. 2026 Jan; 27(1):e70439.
Score: 0.185
-
Bilateral asymmetry of quantitative parenchymal kinetics at ultrafast DCE-MRI predict response to neoadjuvant chemotherapy in patients with HER2+ breast cancer. Magn Reson Imaging. 2023 12; 104:9-15.
Score: 0.157
-
Breast MRI during Neoadjuvant Chemotherapy: Lack of Background Parenchymal Enhancement Suppression and Inferior Treatment Response. Radiology. 2021 11; 301(2):295-308.
Score: 0.137
-
Diffusion-weighted MRI Findings Predict Pathologic Response in Neoadjuvant Treatment of Breast Cancer: The ACRIN 6698 Multicenter Trial. Radiology. 2018 12; 289(3):618-627.
Score: 0.112
-
Highly accurate response prediction in high-risk early breast cancer patients using a biophysical simulation platform. Breast Cancer Res Treat. 2022 11; 196(1):57-66.
Score: 0.037
-
Differences Between Ipsilateral and Contralateral Early Parenchymal Enhancement Kinetics Predict Response of Breast Cancer to Neoadjuvant Therapy. Acad Radiol. 2022 10; 29(10):1469-1479.
Score: 0.036
-
Test-retest repeatability and reproducibility of ADC measures by breast DWI: Results from the ACRIN 6698 trial. J Magn Reson Imaging. 2019 06; 49(6):1617-1628.
Score: 0.028
-
Lymph node wire localization post-chemotherapy: Towards improving the false negative sentinel lymph node biopsy rate in breast cancer patients. Clin Imaging. 2018 Mar - Apr; 48:69-73.
Score: 0.026